The startup develops reformulated biopharmaceutical drugs that utilize new chemical entities to enhance the identification of biologics and small molecules. This approach streamlines regulatory strategies and clinical programs, enabling biotech companies to efficiently meet drug demands and improve patient outcomes.
Funding
$99.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OHFounders
Product
Problem
Many diseases lack effective treatment options, resulting in significant unmet medical needs and reduced quality of life for patients. Current therapies may only address symptoms without targeting the underlying causes of the disease. This is especially true for conditions like major depressive disorder and severe acute pancreatitis, where existing treatments often fall short.
Solution
Arrivo BioVentures is a biopharmaceutical company focused on developing novel, disease-modifying therapies that target the root causes of hard-to-treat diseases. Their pipeline includes two clinical-stage candidates: Forvisirvat (SP-624) for major depressive disorder, particularly in women, and RABI-767 for predicted severe acute pancreatitis. SP-624 is a SIRT6 activator with an epigenetic mechanism of action, designed to address potential divergent gene expression in depressed women. RABI-767, which has received FDA Fast Track designation, is a small molecule pancreatic lipase inhibitor that aims to halt the cascade of fat necrosis, a key driver of tissue injury, systemic toxicity, organ failure, and mortality in severe acute pancreatitis.
Target Audience
The primary target audience includes patients suffering from major depressive disorder, particularly women, and individuals at risk of progressing to severe acute pancreatitis, as well as the healthcare providers who treat these conditions.
Features
- SP-624: A first-in-class SIRT6 activator with an epigenetic mechanism of action for major depressive disorder.
- SP-624: Designed to address potential divergent gene expression in depressed women.
- RABI-767: A small molecule pancreatic lipase inhibitor for patients predicted to advance to severe acute pancreatitis.
- RABI-767: Aims to halt the highly toxic cascade of fat necrosis.
- RABI-767: Received Fast Track Designation from the FDA.